Life Sciences British Columbia

Life Sciences British Columbia is a Canadian non-governmental organization representing the interests of pharmaceutical companies at various levels of government. LifeSciences British Columbia, formerly known as BC Biotech was founded in 1991.

BC Biotech Becomes LifeSciences British Columbia and Charts New Course in Growing Canada’s Bio-Economy

February 15, 2007, Vancouver, BC – BC Biotech announces today a name change to LifeSciences British Columbia. The change in name is reflective of an even broader member association and an expanded Life Sciences Industry view beyond biopharmaceuticals. The organization will now begin to extend its advocacy, public policy development and awareness-building activities to ensure all aspects of the bio-economy continues to grow in British Columbia and Canada.

One of the first steps in making this happen is the impending merger with BC MedTech, the organization representing British Columbia’s medical device sector. Upon approval by BC Biotech members, the two organizations will together form an increased critical mass and stronger voice under the LifeSciences British Columbia moniker.

”Part of this change is to recognize that biotech in British Columbia means more than human health, that it truly affects all aspects of life here – from our forests to our fields, and oceans,” comments Karimah Es Sabar, Executive Director of LifeSciences British Columbia.

The Life Sciences industry extends to agricultural and industrial biotechnology, which include growing and developing industries like aquaculture, forestry and bioproducts. ”It’s not in our best interests to narrowly define our Life Sciences Industry. ¹⁾

Med Biogene Engages The Howard Group Inc. to Provide Investor and Financial Relations Services February 15, 2007 ²⁾

LSBC's sponsors include AbbVie, AbCellera, Acuitas Therapeutics, adMare BioInnovations, Amgen, Amplitude Ventures, Aon, AstraZeneca, Aurinia Pharmaceuticals, Bausch Health, BioTalent Canada, Blake, Cassels & Graydon, Boeringer Ingelheim, Centre for Health Evaluation & Outcome Sciences, Chinook Therapeutics, Clinical Trials BC, Cytiva, Deloitte, EMD Serono, entrepreneurship@UBC, Ernst & Young, Evonik, Farris, Fasken, Gairdner Foundation, Genome British Columbia, GlaxoSmithKline, Gowling WLG, Innovative Medicines Canada, IRICoR, Janssen, LifeLabs, Lumira Ventures, McCarthy Tetrault, Merck, Michael Smith Foundation for Health Research, Northview LifeSciences, Nimbus Synergies, Novartis, Novateur, Novo Nordisk, Oyen Wiggs Green & Mutala, Pfizer, PR Associates, PricewaterhouseCoopers, Roche, Sanofi, Silicon Valley Bank, StarFish Medical, Stemcell Technologies, St. Paul's Hospital Foundation, Takeda, Xenon Pharmaceuticals, and Zymeworks.³⁾